Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 16/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793605 | 1.00 | RORC (0.48) | RORCSTSSIRT2SIRT1NR1H2 | |
| SCHEMBL5202065 | 0.92 | RORC (0.49) | RORCSTSSIRT2SIRT1CCR5 | |
| SCHEMBL5204551 | 0.92 | RORC (0.49) | RORCSTSSIRT2SIRT1CCR5 | |
| SCHEMBL5202070 | 0.92 | RORC (0.49) | RORCSTSSIRT2SIRT1CCR5 | |
| SCHEMBL5203332 | 0.82 | STS (0.39) | RORCSTSCCR5 | |
| SCHEMBL5203325 | 0.82 | STS (0.39) | RORCSTSCCR5 | |
| SCHEMBL5201960 | 0.81 | MEN1 (0.40) | RORCSTS | |
| SCHEMBL5201963 | 0.81 | MEN1 (0.40) | RORCSTS | |
| SCHEMBL5203738 | 0.74 | ITGA4 (0.58) | RORC | |
| SCHEMBL6793873 | 0.70 | ADAM17 (0.37) | STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ICAM1 | RORC 457/4885STS 1122/4885SIRT2 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.